Jianfeng Zhou

16.6k total citations · 1 hit paper
357 papers, 8.0k citations indexed

About

Jianfeng Zhou is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Jianfeng Zhou has authored 357 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Molecular Biology, 138 papers in Oncology and 80 papers in Hematology. Recurrent topics in Jianfeng Zhou's work include CAR-T cell therapy research (88 papers), Lymphoma Diagnosis and Treatment (44 papers) and Virus-based gene therapy research (44 papers). Jianfeng Zhou is often cited by papers focused on CAR-T cell therapy research (88 papers), Lymphoma Diagnosis and Treatment (44 papers) and Virus-based gene therapy research (44 papers). Jianfeng Zhou collaborates with scholars based in China, United States and United Kingdom. Jianfeng Zhou's co-authors include Ding Ma, Ken H. Young, Zijun Y. Xu‐Monette, Liang Huang, Gang Xu, Qinglei Gao, Shixuan Wang, Jiali Cheng, Yang Cao and Min Xiao and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Jianfeng Zhou

348 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

2017 312 citations Jianfeng Zhou et al. profile →

Peers

Jianfeng Zhou

ONCOL

IMMUN

GENET

PFM

David R. Spriggs United States

Delong Liu United States

He Huang China

Jochen K. Lennerz United States

Jie Xu China

Seiji Okada Japan

Daniel M. Sullivan United States

Hans Jørgen Nielsen Denmark

Herman Yeger Canada

Kam M. Hui Singapore

David R. Spriggs United States

Jianfeng Zhou

4.2k ×1.3

4.9k ×1.6

ONCOL

3.0k ×1.9

IMMUN

933 ×0.9

GENET

835 ×0.8

PFM

Citations per year, relative to Jianfeng Zhou Jianfeng Zhou (= 1×) peers David R. Spriggs

Countries citing papers authored by Jianfeng Zhou

Since Specialization

Citations

This map shows the geographic impact of Jianfeng Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianfeng Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianfeng Zhou more than expected).

Fields of papers citing papers by Jianfeng Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianfeng Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianfeng Zhou. The network helps show where Jianfeng Zhou may publish in the future.

Co-authorship network of co-authors of Jianfeng Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Jianfeng Zhou. A scholar is included among the top collaborators of Jianfeng Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianfeng Zhou. Jianfeng Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wenxuan, et al.. (2025). Enhanced solubility, stability, and bioavailability of astilbin via inclusion complexes formation with methyl-β-cyclodextrin. Colloids and Surfaces A Physicochemical and Engineering Aspects. 726. 138088–138088.

Li, Yue, Arnold C.‐M. Yang, Yu Gao, et al.. (2024). Analysis of warping defect formation mechanisms in hot molding of CF/PEEK thin-wall structures and their influence on mechanical properties. Thin-Walled Structures. 207. 112740–112740. 4 indexed citations

Shen, Qiyang, et al.. (2024). Spontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report. BMC Pediatrics. 24(1). 209–209.

Xu, Zhiwen, Xue-Song Sun, Xiang Feng, et al.. (2024). 1391TiP TACTC-2 trial: Efficacy of pembrolizumab ± chemotherapy first-line therapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50% adjusting in accordance with CtDNA. Annals of Oncology. 35. S871–S871. 1 indexed citations

Chen, C., Xinyue Huang, Jianfeng Zhou, et al.. (2023). Migration-inducing gene-7 promotes glioma cell proliferation and invasiveness via activating the MAPK signaling pathway. Neoplasma. 70(4). 534–544. 4 indexed citations

Jin, Jin, Ting Sun, Man Zhang, et al.. (2023). EBV-Encoded MicroRNA-BART17-3p Targets DDX3X and Promotes EBV Infection in EBV-Associated T/Natural Killer–Cell Lymphoproliferative Diseases. Open Forum Infectious Diseases. 10(11). ofad516–ofad516. 4 indexed citations

Wang, Na, Gaoxiang Wang, Liang Huang, et al.. (2022). CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 24(8). 841–849. 14 indexed citations

Xu, Hao, Liang Huang, Wenyue Cao, et al.. (2022). Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma. Cytotherapy. 25(2). 185–191. 2 indexed citations

An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations

10.

Zhou, Jianfeng, Wenjun Wang, Zhongping Yin, et al.. (2021). Quercetin is a promising pancreatic lipase inhibitor in reducing fat absorption in vivo. Food Bioscience. 43. 101248–101248. 53 indexed citations

11.

Zhou, Jianfeng, Guodong Zheng, Wenjun Wang, et al.. (2021). Physicochemical properties and bioavailability comparison of two quercetin loading zein nanoparticles with outer shell of caseinate and chitosan. Food Hydrocolloids. 120. 106959–106959. 66 indexed citations

12.

Dai, Zhenyu, Xuelian Hu, Jianwei Liu, et al.. (2021). Development and functional characterization of novel fully human anti‐CD19 chimeric antigen receptors for T‐cell therapy. Journal of Cellular Physiology. 236(8). 5832–5847. 5 indexed citations

13.

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

14.

Zeng, Chen, Jiali Cheng, Jin Huang, et al.. (2020). Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 22(3). 166–171. 30 indexed citations

15.

Zhou, Mi, Ling Cheng, Xing Chen, et al.. (2018). MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL. Cancer Research. 78(7). 1632–1642. 15 indexed citations

16.

Ding, Wencheng, Zheng Hu, Da Zhu, et al.. (2014). Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells. Clinical Cancer Research. 20(24). 6495–6503. 45 indexed citations

17.

Ma, Xiaoli, Jia Liu, Jiang Wu, et al.. (2010). Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells. Clinical Cancer Research. 16(21). 5165–5176. 11 indexed citations

18.

Ma, Xiaoli, Quanfu Ma, Jia Liu, et al.. (2009). Identification of LIV1 , a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach. Molecular Cancer Therapeutics. 8(11). 3108–3116. 13 indexed citations

19.

Yang, Wanhua, Danfeng Luo, Shixuan Wang, et al.. (2008). TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis. Clinical Cancer Research. 14(17). 5494–5502. 96 indexed citations

20.

Ning, Yaogui, Chen Chen, Ding Ma, et al.. (2007). Cytochrome P 450 Epoxygenase Promotes Human Cancer Metastasis. Cancer Research. 67(14). 6665–6674. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact